Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT04635683
Title Lenalidomide, Umbralisib, and Ublituximab for the Treatment of Relapsed or Refractory Indolent Non-Hodgkin Lymphoma or Mantle Cell Lymphoma
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors Yazeed Sawalha
Indications

marginal zone B-cell lymphoma

Waldenstroem's macroglobulinemia

follicular lymphoma

mantle cell lymphoma

Therapies

Lenalidomide + Ublituximab + Umbralisib

Age Groups: senior | adult
Covered Countries USA


No variant requirements are available.